Triple

T19772730
Position Surface form Disambiguated ID Type / Status
Subject Array BioPharma E474928 entity
Predicate hasTherapy P73562 FINISHED
Object encorafenib
Encorafenib is a small-molecule BRAF inhibitor used in targeted cancer therapy, particularly for tumors harboring BRAF V600 mutations.
 E1394945 NE FINISHED

How this triple was built (4 steps)

Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.

NER Named-entity recognition gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: encorafenib | Statement: [Array BioPharma, hasTherapy, encorafenib]
NED1 Entity disambiguation (via context triple) gpt-5-mini-2025-08-07 
Target entity: encorafenib
Context triple: [Array BioPharma, hasTherapy, encorafenib]
  • A. Libtayo
    Libtayo is a monoclonal antibody immunotherapy drug used primarily to treat certain types of advanced skin and lung cancers by targeting the PD-1 pathway.
  • B. Verzenio
    Verzenio is a prescription cancer medication (abemaciclib) used primarily to treat certain types of hormone receptor–positive, HER2-negative breast cancer.
  • C. Imfinzi
    Imfinzi is a prescription immunotherapy drug (durvalumab) developed by AstraZeneca, primarily used to treat certain types of lung and bladder cancers by helping the immune system attack cancer cells.
  • D. Tagrisso
    Tagrisso is a targeted cancer therapy (osimertinib) used primarily to treat certain types of EGFR-mutated non-small cell lung cancer.
  • E. tucatinib
    Tucatinib is an oral small-molecule tyrosine kinase inhibitor used in the treatment of HER2-positive breast cancer, including cases with brain metastases.
  • F. None of above. chosen
  • G. Unsure - the case is ambiguous/there is not enough information to decide.
NEDg Description generation gpt-5.1
Instruction
Generate a one-sentence description of the target entity. 
You are given a context triple in the form (subject, predicate, object), where the object is the target entity. 
# Instructions
Use the triple to infer relevant information about the entity. Describe the entity based on what is most defining, well-known. 
Avoid repeating the information from the triple, unless really essential.
# Response Format
Return only the sentence: "Description: [one-sentence description of the target entity]"
Input
Entity: encorafenib
Triple: [Array BioPharma, hasTherapy, encorafenib]
Generated description
Encorafenib is a small-molecule BRAF inhibitor used in targeted cancer therapy, particularly for tumors harboring BRAF V600 mutations.
NED2 Entity disambiguation (via description) gpt-5-mini-2025-08-07 
Target entity: encorafenib
Target entity description: Encorafenib is a small-molecule BRAF inhibitor used in targeted cancer therapy, particularly for tumors harboring BRAF V600 mutations.
  • A. Libtayo
    Libtayo is a monoclonal antibody immunotherapy drug used primarily to treat certain types of advanced skin and lung cancers by targeting the PD-1 pathway.
  • B. Verzenio
    Verzenio is a prescription cancer medication (abemaciclib) used primarily to treat certain types of hormone receptor–positive, HER2-negative breast cancer.
  • C. Imfinzi
    Imfinzi is a prescription immunotherapy drug (durvalumab) developed by AstraZeneca, primarily used to treat certain types of lung and bladder cancers by helping the immune system attack cancer cells.
  • D. Tagrisso
    Tagrisso is a targeted cancer therapy (osimertinib) used primarily to treat certain types of EGFR-mutated non-small cell lung cancer.
  • E. tucatinib
    Tucatinib is an oral small-molecule tyrosine kinase inhibitor used in the treatment of HER2-positive breast cancer, including cases with brain metastases.
  • F. None of above. chosen

Provenance (5 batches)

The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.

Step Stage Batch ID Status When
creating Elicitation batch_69d8e51a43a08190956bc6df13c91a77 completed April 10, 2026, 11:55 a.m.
NER Named-entity recognition batch_69e6535ce4d08190a1dfca2df95a8631 completed April 20, 2026, 4:25 p.m.
NED1 Entity disambiguation (via context triple) batch_6a07bd74937081908b81d144aa89c5f3 completed May 16, 2026, 12:42 a.m.
NEDg Description generation batch_6a07be450e608190a008095b0502b2d3 completed May 16, 2026, 12:45 a.m.
NED2 Entity disambiguation (via description) batch_6a07bed4c8d8819094fafce7eee69ee7 completed May 16, 2026, 12:48 a.m.
Created at: April 10, 2026, 1:48 p.m.